Mangoceuticals Files to Sell 2.64M Shares of Common Stock
Mangoceuticals files to sell 2.64M shares of common stock for holders
Discover Tomorrow's Bullish Stocks Today
Analyst Views on MGRX
About MGRX
About the author

Nasdaq Rises More Than 1%; Lamb Weston Stock Drops After Q2 Earnings Report
U.S. Stock Market Performance: U.S. stocks saw gains, with the Nasdaq Composite up over 1%, while the Dow and S&P 500 also rose, reflecting positive trading activity.
Nike's Earnings Report: Nike's shares fell approximately 10% despite reporting better-than-expected earnings and sales, due to a decline in gross margins for the second consecutive quarter.
Notable Stock Movements: Autozi Internet Technology shares surged 54% after a significant investment announcement, while Amicus Therapeutics rose 31% following an acquisition deal, contrasting with declines in Lamb Weston and BlackBerry shares.
Global Market Trends: European and Asian markets closed higher, with notable gains in major indices, while U.S. existing home sales increased slightly, indicating a stable economic environment.

Mangoceuticals Closes $2.5 Million Registered Direct Offering
- Successful Financing: Mangoceuticals has completed a registered direct offering and concurrent private placement with institutional investors, raising approximately $2.5 million, which enhances the company's liquidity for future growth initiatives.
- Transaction Details: The offering involved the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant, priced at $1.295 per unit, adhering to Nasdaq market regulations.
- Use of Proceeds: The company plans to utilize the net proceeds from the offerings, combined with existing cash, for general corporate purposes and working capital, aiming to enhance operational efficiency and market competitiveness.
- Legal Compliance: The securities issuance was conducted under an effective S-3 registration statement, ensuring compliance and laying the groundwork for future capital market activities, reflecting the company's commitment to regulatory adherence.






